Daniel P. Petrylak, MD | Authors

Crest Hill



Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer

April 19, 2021

ONCOLOGY® editorial board member E. David Crawford, MD, and colleagues, propose a new model for guiding the treatment of prostate cancer that focuses on a “transitional state,” which occurs during the interval of progression to metastatic castration-resistant prostate cancer.

Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer

March 15, 2018

An 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.

New Agents for the Treatment of Advanced Bladder Cancer

June 15, 2016

This article will review select novel targets and approaches relevant to urothelial cancer.

ASCO: Role of Chemotherapy and Novel Targeted Agents in Prostate Cancer

May 30, 2014

As part of our coverage of ASCO's Annual Meeting, we discuss the role of chemotherapy in prostate cancer, as well as study results on novel targeted approaches and agents in development for prostate cancer that will be presented at the meeting.

Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases: Mechanism of Action of Radium-223 Chloride (Alpharadin) and Radiation

April 15, 2012

This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin).

Evolving Therapeutic Paradigms for Advanced Prostate Cancer: What's Needed to Make Optimal Use of the New Treatments

May 16, 2011

The article by Ruch and Hussain provides a comprehensive overview of the progress that has been made in translating basic science findings in prostate cancer biology to clinical trials.